
Release date: 2024-08-06 17:08:49 Article From: Lucius Laos Recommended: 313
The price of Exkivity varies depending on a number of factors, including the version of the drug (innovator or generic), manufacturer, sales channel, and regional policies.
As a targeted therapy for specific types of non-small cell lung cancer, the price of Exkivity is relatively high. This is mainly due to the combination of factors such as R&D costs, production costs, and market positioning.
The price of the original drug (Anweili) of Exkivity is relatively expensive, about 37,588 yuan/28 days, that is, the price of one treatment cycle may be close to or exceed 100,000 yuan. This price is a large financial burden for many patients.
The generic version may be relatively inexpensive. The generic drug of Exkivity produced by Lucius Pharmaceutical Co., Ltd. is 40mg*120 tablets, and the price is about 4,500 yuan.
However, it should be noted that the specific price and quality may vary depending on the manufacturer and regional policies, and the specific price at the time of actual purchase shall prevail.
Lucius Pharmaceutical Co., Ltd. has strict standards in the production and quality control of pharmaceuticals and has obtained several important certifications. These certifications not only prove the company's production capacity and product quality but also lay a solid foundation for the company's future development. Here's a closer look at its quality standards or certifications:
Lucius Pharmaceutical's manufacturing facilities and operations are strictly in compliance with the World Health Organization's (WHO) Good Manufacturing Practices (GMP), as well as GMP standards in Laos, the European Union, the United States, and China. This ensures that the quality and safety of the company's products reach a world-class level.
The company has obtained marketing approval certificates for a number of anti-cancer drugs, including capmatinib approved by the Lao Drug Regulatory Bureau, which further proves the legality and effectiveness of its products.
【Warm tips】When using Exkivity, please inform your doctor of all the drugs you are using (including prescription drugs, over-the-counter drugs, Chinese medicines, health products, etc.) to avoid drug interactions, which may affect the efficacy or increase the risk of adverse reactions.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:[list:visits]2024-09-07
Before 2020, there were only a handful of legally approved local pharmaceutical manufacturers in Lao···【more】
Recommended:[list:visits]2026-07-07
Lucius Pharmaceuticals (Lao) Co., Ltd. has launched a generic version of elagolix sodium (trade name···【more】
Recommended:[list:visits]2026-06-07
Contraindications for Bempedoic Acid (Nilemdo)Bempedoic acid (Nilemdo) is strictly contraindicated i···【more】
Recommended:[list:visits]2026-03-07
With generic drugs as its core, Laos' pharmaceutical industry has formed an industrial pattern f···【more】
Recommended:[list:visits]2026-02-07
The pharmaceutical industry in Laos started late and is limited in scale, with domestic drug supply ···【more】
Recommended:[list:visits]2026-01-07
Lucius Pharmaceuticals (Lao) Co., Ltd is a Lao pharmaceutical company established in 2020, headquart···【more】
Recommended:[list:visits]2026-30-06

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com